Quantification of the effects of thrombin activatable fibrinolysis inhibitor and α2-antiplasmin on fibrinolysis in normal human plasma

Blood Coagulation and Fibrinolysis

Volumn 18, Issue 1, 2007, Pages 29-33

  Nielsen, Vance G ^a   Ellis, Truitt C ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

2 antiplasmin; Fibrinolysis; Thrombelastography; Thrombin activatable fibrinolysis inhibitor; Tissue type plasminogen activator

Indexed keywords

ALPHA 2 ANTIPLASMIN; CARBOXYPEPTIDASE; ENZYME ANTIBODY; KAOLIN; PROTEIN ANTIBODY; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOPLASTIN; TISSUE PLASMINOGEN ACTIVATOR;

ARTICLE; BLOOD CLOTTING; CONCENTRATION RESPONSE; CONTROLLED STUDY; FIBRINOLYSIS; HUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; THROMBOELASTOGRAPHY;

ANTIBODIES; ANTIPLASMIN; BLOOD CELLS; BLOOD COAGULATION; CARBOXYPEPTIDASE U; CELLS, CULTURED; FIBRINOLYSIS; HUMANS; KINETICS; METHODS; PLANT PROTEINS; THROMBELASTOGRAPHY;

EID: 33845738884     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e3280129afe     Document Type: Article

References (21)

1. Minowa H, Takahashi Y, Tanaka T, Naganuma K, Ida S, Ichiro M, et al. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. Haemostasis 1999; 29:286-291.
2. 2-plasmin inhibitor or plasminogen activator-inhibitor-1. Haemophilia 2004; 10:669-674.
3. 2-plasmin inhibitor deficiency. Am J Hematol 1994; 45:16-24.
4. 2-plasmin inhibitor deficiency in patients with severe head injury. Neurosurgery 2001; 49:1084-1090.
5. de Jonge J, Groenland THN, Metselaar HJ, Ijzermans JNM, van Vliet HHDM, Visser L, et al. Fibrinolysis during liver transplantation is enhanced by using solvent/detergent virus-inactivated plasma (ESDEP®). Anesth Analg 2002; 94:1127-1131.
6. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273:27176-27181.
7. Schneider M, Nesheim M. A study of the protection of plasmin from antiplasmin inhibition within an intact fibrin clot during the course of clot lysis. J Biol Chem 2004; 279:13333-13339.
8. Schneider M, Brufatto N, Neill E, Nesheim M. Activated thrombin-activatable fibrinolysis inhibitor reduces the ability of high molecular weight fibrin degradation products to protect plasmin from antiplasmin. J Biol Chem 2004; 279:13340-13345.
9. Nielsen VG, Steenwyk BL, Gurley WQ. Contact activation prolongs clot lysis time in human plasma: role of thrombin activatable fibrinolysis inhibitor and factor XIII. J Heart Lung Transplant 2006; 25:1247-1252.
10. Nielsen VG, Cohen BM, Cohen E. Elastic modulus-based thrombelastographic quantification of plasma clot fibrinolysis with progressive plasminogen activation. Blood Coagul Fibrinolysis 2006; 17:75-81.
11. Nielsen VG. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg 2006; 81:1720-1727.
12. Mutch NJ, Moore NR, Wang E, Booth NA. Thrombus lysis by uPA, scuPA and tPA is regulated by plasma TAFI. J Thromb Haemost 2003; 1:2000-2007.
13. Cruden NLM, Lawes L, Masson P, Robinson SD, Ludlam CA, Newby DE. Inhibition of thrombin activatable fibrinolysis inhibitor augments fibrinolysis in human whole blood. J Thromb Haemost 2005; 3:2351-2353.
14. Meijers JCM, Oudijk ED, Mosnier LO, Bos R, Bouma BN, Nieuwenhuis HK, et al. Reduced activity of TAFI (thrombin-activatable fibrinolysis inhibitor) in acute promyelocytic leukaemia. Br J Haematol 2000; 108:518-523.
15. Mosnier LO, Lisman T, van den Berg HM, Nieuwenhuis HK, Meijers JC, Bouma BN. The defective down regulation of fibrinolysis in haemophilia A can be restored by increasing the TAFI plasma concentration. Thromb Haemost 2001; 86:1035-1039.
16. Dai L, Mitchell M, Savidge G, Alhaq A. The profibrinolytic effect of plasma thrombomodulin in factor XI deficiency and its implications in hemostasis. J Thromb Haemost 2004; 2:2200-2204.
17. Saibeni S, Bottasso B, Spina L, Bajetta M, Danese S, Gasbarrini A, et al. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 2004; 99:1966-1970.
18. Hataji O, Taguchi O, Gabazza EC, Yuda H, D'Alessandro-Gabazza CN, Fujimoto H, et al. Increased circulating levels of thrombin-activatable fibrinolysis inhibitor in lung cancer patients. Am J Hematol 2004; 76:214-219.
19. Leebeek FWG, Van Goor MPJ, Guimaraes AHC, Brouwers GJ, De Maat MPM, Dippel DWJ, et al. High functional levels of thrombin-activatable fibrinolysis inhibitor are associated with an increased risk of first ischemic stroke. J Thromb Haemost 2005; 3:2211-2218.
20. McCrath DJ, Cerboni E, Frumento RJ, Hirsh AL, Bennett-Guerrero E. Thromboelastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005; 100:1576-1583.
21. Gurbel PA, Bliden KP, Guyer K, Cho PW, Zaman KA, Kreutz RP, et al. Platelet reactivity in patients and recurrent events post-stenting; results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005; 46:1820-1826.